Discordance in activated partial thromboplastin time and anti-factor Xa levels in COVID-19 patients on heparin therapy

Thromb Res. 2021 Feb:198:79-82. doi: 10.1016/j.thromres.2020.11.030. Epub 2020 Nov 28.

Abstract

  1. •

    aPTT correlates poorly with anti-Xa in COVID-19 patients receiving unfractionated heparin.

  2. •

    aPTT potentially underestimates heparin activity compared with anti-Xa in COVID-19 patients receiving unfractionated heparin.

  3. •

    Elevated fibrinogen levels did not correlate with refractory aPTT in COVID-19 patients.

Keywords: Activated partial thromboplastin time; Anti-factor Xa assay; COVID-19; Unfractionated heparin.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Coagulation / drug effects*
  • COVID-19 / blood
  • COVID-19 / diagnosis
  • COVID-19 Drug Treatment*
  • Data Warehousing
  • Drug Monitoring
  • Electronic Health Records
  • Factor Xa / metabolism*
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Heparin / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Partial Thromboplastin Time*
  • Predictive Value of Tests
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Factor Xa Inhibitors
  • Heparin
  • Factor Xa